Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05739006 | Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies | unknown | Phase 1 | 131 | BiocadINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05961111 | A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05928962 | An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas | unknown | Phase 1 | 10 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 10, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05451407 | Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma | unknown | Phase 1 | 50 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT03803397 | Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma | unknown | Phase 1 | 10 | PrimeVax Immuno-Oncology Inc.INDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT03989895 | Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma | unknown | Phase 1 | 10 | PrimeVax Immuno-Oncology Inc.INDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT03990493 | Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma | unknown | Phase 1 | 10 | PrimeVax Immuno-Oncology Inc.INDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT05827289 | 'Cancer Patients Better Life Experience'(CAPABLE) | unknown | N/A | 36 | The Netherlands Cancer InstituteOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05223218 | Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study | unknown | — | 500 | Namida LabINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05478473 | Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma | unknown | N/A | 43 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05889481 | Morphological, Genetic and Tumour Microenvironment Characterisation in Uveal Melanoma(MicroGenUM) | unknown | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05906277 | Biobanking and New Biomolecular Metrics(Melamoma4p) | unknown | N/A | 300 | Regina Elena Cancer InstituteOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05106023 | To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma | unknown | Phase 2 | 31 | Yong ChenOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05263453 | HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation | unknown | Phase 2 | 104 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT05823246 | Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma | unknown | Phase 2 | 66 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 26, 2023 | clinicaltrials |
| NCT05854589 | Effect of Topical Application of Hypertonic Saline on Melanoma on Its Sizes and Number. | unknown | Phase 2 | 20 | Rafik BatroussyOTHER | 0 | May 11, 2023 | clinicaltrials |
| NCT03683550 | Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma | unknown | N/A | 836 | University Hospital, EssenOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05723432 | KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma | unknown | Phase 1 / Phase 2 | 84 | Shanghai Kanda Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05827770 | The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma | unknown | Phase 2 | 20 | Yong ChenOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03313544 | Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 | unknown | Phase 4 | 50 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT03528408 | Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma | unknown | Phase 2 | 52 | Suthee RapisuwonOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT03743298 | Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma | unknown | Phase 1 | 20 | Aivita Biomedical, Inc.INDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT04821570 | To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment(CANINE) | unknown | — | 500 | University of Kansas Medical CenterOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05156515 | PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor | unknown | N/A | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03132675 | Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment(Keynote-695) | unknown | Phase 2 | 143 | OncoSec Medical IncorporatedINDUSTRY | 5 | Mar 27, 2023 | clinicaltrials |
| NCT05783882 | Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma(FLAT) | unknown | Phase 3 | 114 | BiocadINDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05767879 | (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma | unknown | Phase 2 | 28 | Leiden University Medical CenterOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05750511 | Multicenter Tissue Registry in Melanoma(TRIM) | unknown | — | 1,000 | Dermatologic Cooperative Oncology GroupOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05744076 | Analysis of Circulating Exosomes in Melanoma Patients(EXOMEL1) | unknown | — | 150 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT03534635 | Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS) | unknown | Phase 2 | 30 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04747561 | Clinical Application of 18F-PEG3-FPN PET Imaging in Diagnosis and Staging of Malignant Melanoma | unknown | N/A | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05645484 | The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma | unknown | — | 100 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04107168 | Microbiome Immunotherapy Toxicity and Response Evaluation | unknown | — | 1,800 | CCTU- Cancer ThemeOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05664139 | Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Feb 8, 2023 | clinicaltrials |
| NCT03166397 | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | unknown | Phase 2 | 30 | Sheba Medical CenterOTHER_GOV | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05145829 | Exploring an Alternative Pre-operative SLN Mapping Method Using a Magnetic Tracer and MRI for Melanoma Patients(SCARLETT) | unknown | N/A | 40 | Zuyderland Medisch CentrumOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT04436406 | PD-L1 Expression in Cancer (PECan Study).(PECan) | unknown | N/A | 30 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05641012 | Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma(Helioma) | unknown | — | 100 | Institut Jean-GodinotOTHER | 0 | Dec 7, 2022 | clinicaltrials |
| NCT04633902 | Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation | unknown | Phase 2 | 41 | California Pacific Medical Center Research InstituteOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05077280 | A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma | unknown | Phase 2 | 40 | California Pacific Medical Center Research InstituteOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05051865 | To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma | unknown | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05406466 | Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT00986661 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | unknown | Phase 1 | 78 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT02036086 | Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases | unknown | Phase 2 | 24 | Sunnybrook Health Sciences CentreOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT01955915 | Blood Vessel Patterns in Small Choroidal Tumors | unknown | — | 15 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 12, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Aug 2, 2023source: clinicaltrials